CXCL1 Specific Neutra™ Antibody Products

Are you struggling with prolonged drug discovery timelines or inconsistent outcomes in inflammation and oncology research? Creative Biolabs' CXCL1 specific Neutra™ antibody products overcome these challenges using advanced single-B-cell screening and antibody engineering, empowering precise target neutralization to accelerate therapeutic validation and preclinical development.

Introduction to CXCL1

C-X-C motif chemokine ligand 1 (CXCL1) is a small, secreted chemokine belonging to the CXC family, primarily produced by macrophages, endothelial cells, and epithelial cells. It functions as a potent chemoattractant for neutrophils via binding to its cognate receptor CXCR2. CXCL1 is critical in orchestrating innate immune responses and is highly upregulated under inflammatory or hypoxic conditions. Its dysregulation is closely linked to chronic inflammation, tumorigenesis, and autoimmune disorders.

• Structural Features

CXCL1 exists as a monomeric protein stabilized by disulfide bonds, with a conserved Glu-Leu-Arg (ELR) motif essential for receptor activation. Structural studies reveal that dimerization of CXCL1 enhances its binding avidity to glycosaminoglycans (GAGs) on endothelial surfaces, facilitating leukocyte recruitment. Mutations in the ELR motif or disruption of GAG interactions abolish its chemotactic activity, highlighting structure-function relationships vital for therapeutic targeting.

• Associated Signaling Pathways

CXCL1-CXCR2 signaling activates multiple downstream pathways:

1. NF-κB and MAPK Pathways: Amplify pro-inflammatory cytokine production and cell survival.

2. PI3K/AKT Pathway: Promotes angiogenesis and tumor cell proliferation.

3. JAK/STAT Pathway: Modulates immune cell infiltration in the tumor microenvironment.

CXCL1 also cross-talks with interleukin-17 (IL-17) to exacerbate inflammatory responses in autoimmune diseases.

• Disease Relevance

CXCL1 overexpression drives pathologies such as rheumatoid arthritis, psoriasis, atherosclerosis, and multiple cancer types (e.g., breast, colorectal, and lung cancers). In cancer, CXCL1 promotes neutrophil-rich immunosuppressive microenvironments, metastasis, and resistance to chemotherapy. Its elevated serum levels correlate with poor prognosis, underscoring its value as a therapeutic and diagnostic biomarker.

Fig.1 Importance of CXCL1 and neutrophils in rheumatoid arthritis.¹

Applications of CXCL1 Neutralizing Antibodies in Clinical Research

• Therapeutic Intervention in Chronic Inflammatory Diseases

CXCL1-neutralizing antibodies mitigate neutrophil-driven tissue damage in rheumatoid arthritis and inflammatory bowel disease. Preclinical data demonstrate reduced joint swelling and colon inflammation, supporting their potential as biologic therapies.

• Oncology and Immunotherapy Development

In cancer, CXCL1 blockade disrupts stromal-tumor crosstalk, slowing metastasis and improving immune checkpoint inhibitor efficacy. Antibodies combined with PD-1 inhibitors show synergistic tumor regression in murine melanoma models.

• Respiratory Disease Management

CXCL1 inhibition alleviates neutrophilic inflammation in chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Antibody-treated models exhibit reduced airway hyperresponsiveness and mucus production.

• Diagnostic and Prognostic Tool Development

Anti-CXCL1 antibodies enable precise quantification of serum CXCL1 levels, aiding patient stratification in clinical trials. They also serve as imaging probes to monitor CXCL1 expression in tumor biopsies.

Our Anti-CXCL1 Antibodies

Creative Biolabs' anti-CXCL1 neutralizing antibodies are engineered to disrupt CXCL1-CXCR2 interactions with sub-nanomolar affinity. These antibodies exhibit exceptional specificity, validated across ELISA, flow cytometry, and in vivo models. Key advantages include:

• Blockade of Neutrophil Recruitment: Effectively inhibits chemotaxis in inflammatory models.
• Tumor Microenvironment Modulation: Reduces pro-tumorigenic signaling and enhances chemotherapy sensitivity.
• Cross-Reactivity Testing: Verified for human and murine CXCL1, enabling translational research.

Our antibodies support functional studies in immune cell migration assays, xenograft models, and biomarker validation, providing robust tools for therapeutic discovery.

Creative Biolabs offers CXCL1 specific Neutra™ antibody products with unmatched specificity and functionality for advancing therapeutic and diagnostic research. Engineered to meet stringent preclinical standards, these antibodies accelerate your path from target validation to clinical translation.

Contact our scientific team today to explore custom solutions for your CXCL1-focused projects.

REFERENCE

1. Korbecki, Jan, et al. "The importance of CXCL1 in physiology and noncancerous diseases of bone, bone marrow, muscle and the nervous system." International journal of molecular sciences 23.8 (2022): 4205. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms23084205